nodes	percent_of_prediction	percent_of_DWPC	metapath
Verteporfin—White blood cell count decreased—Mitoxantrone—lymphatic system cancer	0.0143	0.0143	CcSEcCtD
Verteporfin—Dermatitis bullous—Mechlorethamine—lymphatic system cancer	0.014	0.014	CcSEcCtD
Verteporfin—Hearing impaired—Fludarabine—lymphatic system cancer	0.0125	0.0125	CcSEcCtD
Verteporfin—Myasthenia—Carmustine—lymphatic system cancer	0.0121	0.0121	CcSEcCtD
Verteporfin—Sunburn—Methotrexate—lymphatic system cancer	0.0117	0.0117	CcSEcCtD
Verteporfin—Hyperaesthesia—Bleomycin—lymphatic system cancer	0.0111	0.0111	CcSEcCtD
Verteporfin—Scotoma—Carmustine—lymphatic system cancer	0.0101	0.0101	CcSEcCtD
Verteporfin—Extravasation—Bleomycin—lymphatic system cancer	0.01	0.01	CcSEcCtD
Verteporfin—Sleep disorder—Fludarabine—lymphatic system cancer	0.01	0.01	CcSEcCtD
Verteporfin—Injection site pain—Carmustine—lymphatic system cancer	0.00935	0.00935	CcSEcCtD
Verteporfin—Haemoglobin—Mechlorethamine—lymphatic system cancer	0.00929	0.00929	CcSEcCtD
Verteporfin—Haemorrhage—Mechlorethamine—lymphatic system cancer	0.00925	0.00925	CcSEcCtD
Verteporfin—Visual disturbance—Fludarabine—lymphatic system cancer	0.00914	0.00914	CcSEcCtD
Verteporfin—Liver function test abnormal—Teniposide—lymphatic system cancer	0.0091	0.0091	CcSEcCtD
Verteporfin—Extravasation—Carmustine—lymphatic system cancer	0.00875	0.00875	CcSEcCtD
Verteporfin—Extravasation—Vincristine—lymphatic system cancer	0.00835	0.00835	CcSEcCtD
Verteporfin—Extravasation—Mitoxantrone—lymphatic system cancer	0.00814	0.00814	CcSEcCtD
Verteporfin—Liver function test abnormal—Fludarabine—lymphatic system cancer	0.00799	0.00799	CcSEcCtD
Verteporfin—Raised liver function tests—Methotrexate—lymphatic system cancer	0.00766	0.00766	CcSEcCtD
Verteporfin—Injection site reaction—Carmustine—lymphatic system cancer	0.00759	0.00759	CcSEcCtD
Verteporfin—Musculoskeletal pain—Vincristine—lymphatic system cancer	0.00738	0.00738	CcSEcCtD
Verteporfin—Sweating—Teniposide—lymphatic system cancer	0.00728	0.00728	CcSEcCtD
Verteporfin—Vertigo—Mechlorethamine—lymphatic system cancer	0.00723	0.00723	CcSEcCtD
Verteporfin—Haemoglobin—Teniposide—lymphatic system cancer	0.00685	0.00685	CcSEcCtD
Verteporfin—Haemorrhage—Teniposide—lymphatic system cancer	0.00682	0.00682	CcSEcCtD
Verteporfin—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.0068	0.0068	CcSEcCtD
Verteporfin—Pneumonia—Fludarabine—lymphatic system cancer	0.00671	0.00671	CcSEcCtD
Verteporfin—Acute coronary syndrome—Fludarabine—lymphatic system cancer	0.00658	0.00658	CcSEcCtD
Verteporfin—Myocardial infarction—Fludarabine—lymphatic system cancer	0.00654	0.00654	CcSEcCtD
Verteporfin—Skin disorder—Mechlorethamine—lymphatic system cancer	0.00638	0.00638	CcSEcCtD
Verteporfin—Flushing—Teniposide—lymphatic system cancer	0.00633	0.00633	CcSEcCtD
Verteporfin—Haemoglobin—Fludarabine—lymphatic system cancer	0.00602	0.00602	CcSEcCtD
Verteporfin—Haemorrhage—Fludarabine—lymphatic system cancer	0.00599	0.00599	CcSEcCtD
Verteporfin—Hypoaesthesia—Fludarabine—lymphatic system cancer	0.00596	0.00596	CcSEcCtD
Verteporfin—Pharyngitis—Fludarabine—lymphatic system cancer	0.00595	0.00595	CcSEcCtD
Verteporfin—Visual impairment—Fludarabine—lymphatic system cancer	0.00577	0.00577	CcSEcCtD
Verteporfin—Diplopia—Carmustine—lymphatic system cancer	0.00554	0.00554	CcSEcCtD
Verteporfin—Anaemia—Teniposide—lymphatic system cancer	0.00548	0.00548	CcSEcCtD
Verteporfin—Malnutrition—Fludarabine—lymphatic system cancer	0.00521	0.00521	CcSEcCtD
Verteporfin—Hypertension—Teniposide—lymphatic system cancer	0.00512	0.00512	CcSEcCtD
Verteporfin—Liver function test abnormal—Carmustine—lymphatic system cancer	0.00512	0.00512	CcSEcCtD
Verteporfin—Chest pain—Teniposide—lymphatic system cancer	0.00505	0.00505	CcSEcCtD
Verteporfin—Pneumonia—Bleomycin—lymphatic system cancer	0.00492	0.00492	CcSEcCtD
Verteporfin—Muscular weakness—Carmustine—lymphatic system cancer	0.00489	0.00489	CcSEcCtD
Verteporfin—Oedema—Teniposide—lymphatic system cancer	0.00484	0.00484	CcSEcCtD
Verteporfin—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00484	0.00484	CcSEcCtD
Verteporfin—Ill-defined disorder—Fludarabine—lymphatic system cancer	0.00484	0.00484	CcSEcCtD
Verteporfin—Blood creatinine increased—Mitoxantrone—lymphatic system cancer	0.00483	0.00483	CcSEcCtD
Verteporfin—Acute coronary syndrome—Bleomycin—lymphatic system cancer	0.00482	0.00482	CcSEcCtD
Verteporfin—Anaemia—Fludarabine—lymphatic system cancer	0.00482	0.00482	CcSEcCtD
Verteporfin—Myocardial infarction—Bleomycin—lymphatic system cancer	0.0048	0.0048	CcSEcCtD
Verteporfin—Malaise—Fludarabine—lymphatic system cancer	0.0047	0.0047	CcSEcCtD
Verteporfin—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00468	0.00468	CcSEcCtD
Verteporfin—Muscular weakness—Vincristine—lymphatic system cancer	0.00467	0.00467	CcSEcCtD
Verteporfin—Pruritus—Mechlorethamine—lymphatic system cancer	0.00465	0.00465	CcSEcCtD
Verteporfin—Cough—Fludarabine—lymphatic system cancer	0.00455	0.00455	CcSEcCtD
Verteporfin—Arthralgia—Fludarabine—lymphatic system cancer	0.00444	0.00444	CcSEcCtD
Verteporfin—Haemoglobin—Bleomycin—lymphatic system cancer	0.00441	0.00441	CcSEcCtD
Verteporfin—Haemorrhage—Bleomycin—lymphatic system cancer	0.00439	0.00439	CcSEcCtD
Verteporfin—Discomfort—Fludarabine—lymphatic system cancer	0.00439	0.00439	CcSEcCtD
Verteporfin—Hypoaesthesia—Bleomycin—lymphatic system cancer	0.00437	0.00437	CcSEcCtD
Verteporfin—Dyspnoea—Teniposide—lymphatic system cancer	0.00432	0.00432	CcSEcCtD
Verteporfin—Pneumonia—Carmustine—lymphatic system cancer	0.0043	0.0043	CcSEcCtD
Verteporfin—Oedema—Fludarabine—lymphatic system cancer	0.00426	0.00426	CcSEcCtD
Verteporfin—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00417	0.00417	CcSEcCtD
Verteporfin—Photosensitivity reaction—Vincristine—lymphatic system cancer	0.00417	0.00417	CcSEcCtD
Verteporfin—Rash—Mechlorethamine—lymphatic system cancer	0.00414	0.00414	CcSEcCtD
Verteporfin—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00414	0.00414	CcSEcCtD
Verteporfin—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00411	0.00411	CcSEcCtD
Verteporfin—Pneumonia—Vincristine—lymphatic system cancer	0.0041	0.0041	CcSEcCtD
Verteporfin—Flushing—Bleomycin—lymphatic system cancer	0.00408	0.00408	CcSEcCtD
Verteporfin—Extravasation—Methotrexate—lymphatic system cancer	0.00405	0.00405	CcSEcCtD
Verteporfin—Acute coronary syndrome—Vincristine—lymphatic system cancer	0.00402	0.00402	CcSEcCtD
Verteporfin—Myocardial infarction—Vincristine—lymphatic system cancer	0.004	0.004	CcSEcCtD
Verteporfin—Pneumonia—Mitoxantrone—lymphatic system cancer	0.00399	0.00399	CcSEcCtD
Verteporfin—Feeling abnormal—Teniposide—lymphatic system cancer	0.00399	0.00399	CcSEcCtD
Verteporfin—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.00391	0.00391	CcSEcCtD
Verteporfin—Sweating—Vincristine—lymphatic system cancer	0.00391	0.00391	CcSEcCtD
Verteporfin—Nausea—Mechlorethamine—lymphatic system cancer	0.0039	0.0039	CcSEcCtD
Verteporfin—Myocardial infarction—Mitoxantrone—lymphatic system cancer	0.00389	0.00389	CcSEcCtD
Verteporfin—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00388	0.00388	CcSEcCtD
Verteporfin—Conjunctivitis—Mitoxantrone—lymphatic system cancer	0.00386	0.00386	CcSEcCtD
Verteporfin—Haemoglobin—Carmustine—lymphatic system cancer	0.00385	0.00385	CcSEcCtD
Verteporfin—Urticaria—Teniposide—lymphatic system cancer	0.00385	0.00385	CcSEcCtD
Verteporfin—Haemorrhage—Carmustine—lymphatic system cancer	0.00383	0.00383	CcSEcCtD
Verteporfin—Body temperature increased—Teniposide—lymphatic system cancer	0.00383	0.00383	CcSEcCtD
Verteporfin—Hypoaesthesia—Carmustine—lymphatic system cancer	0.00381	0.00381	CcSEcCtD
Verteporfin—Sweating—Mitoxantrone—lymphatic system cancer	0.00381	0.00381	CcSEcCtD
Verteporfin—Dyspnoea—Fludarabine—lymphatic system cancer	0.00379	0.00379	CcSEcCtD
Verteporfin—Visual impairment—Carmustine—lymphatic system cancer	0.00369	0.00369	CcSEcCtD
Verteporfin—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00367	0.00367	CcSEcCtD
Verteporfin—Inflammation—Methotrexate—lymphatic system cancer	0.00365	0.00365	CcSEcCtD
Verteporfin—Hypoaesthesia—Vincristine—lymphatic system cancer	0.00364	0.00364	CcSEcCtD
Verteporfin—Constipation—Fludarabine—lymphatic system cancer	0.00364	0.00364	CcSEcCtD
Verteporfin—Pain—Fludarabine—lymphatic system cancer	0.00364	0.00364	CcSEcCtD
Verteporfin—Eye disorder—Carmustine—lymphatic system cancer	0.00358	0.00358	CcSEcCtD
Verteporfin—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.00358	0.00358	CcSEcCtD
Verteporfin—Hypersensitivity—Teniposide—lymphatic system cancer	0.00357	0.00357	CcSEcCtD
Verteporfin—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00356	0.00356	CcSEcCtD
Verteporfin—Flushing—Carmustine—lymphatic system cancer	0.00356	0.00356	CcSEcCtD
Verteporfin—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00355	0.00355	CcSEcCtD
Verteporfin—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00354	0.00354	CcSEcCtD
Verteporfin—Anaemia—Bleomycin—lymphatic system cancer	0.00353	0.00353	CcSEcCtD
Verteporfin—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00351	0.00351	CcSEcCtD
Verteporfin—Asthenia—Teniposide—lymphatic system cancer	0.00347	0.00347	CcSEcCtD
Verteporfin—Malaise—Bleomycin—lymphatic system cancer	0.00345	0.00345	CcSEcCtD
Verteporfin—Pruritus—Teniposide—lymphatic system cancer	0.00343	0.00343	CcSEcCtD
Verteporfin—Cardiac disorder—Vincristine—lymphatic system cancer	0.0034	0.0034	CcSEcCtD
Verteporfin—Body temperature increased—Fludarabine—lymphatic system cancer	0.00336	0.00336	CcSEcCtD
Verteporfin—Malnutrition—Carmustine—lymphatic system cancer	0.00334	0.00334	CcSEcCtD
Verteporfin—Cough—Bleomycin—lymphatic system cancer	0.00334	0.00334	CcSEcCtD
Verteporfin—Angiopathy—Vincristine—lymphatic system cancer	0.00332	0.00332	CcSEcCtD
Verteporfin—Chest pain—Bleomycin—lymphatic system cancer	0.00326	0.00326	CcSEcCtD
Verteporfin—Back pain—Carmustine—lymphatic system cancer	0.00323	0.00323	CcSEcCtD
Verteporfin—Discomfort—Bleomycin—lymphatic system cancer	0.00322	0.00322	CcSEcCtD
Verteporfin—Vision blurred—Carmustine—lymphatic system cancer	0.00315	0.00315	CcSEcCtD
Verteporfin—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00314	0.00314	CcSEcCtD
Verteporfin—Oedema—Bleomycin—lymphatic system cancer	0.00312	0.00312	CcSEcCtD
Verteporfin—Anaemia—Carmustine—lymphatic system cancer	0.00308	0.00308	CcSEcCtD
Verteporfin—Back pain—Vincristine—lymphatic system cancer	0.00308	0.00308	CcSEcCtD
Verteporfin—Asthenia—Fludarabine—lymphatic system cancer	0.00305	0.00305	CcSEcCtD
Verteporfin—Rash—Teniposide—lymphatic system cancer	0.00305	0.00305	CcSEcCtD
Verteporfin—Dermatitis—Teniposide—lymphatic system cancer	0.00305	0.00305	CcSEcCtD
Verteporfin—Headache—Teniposide—lymphatic system cancer	0.00303	0.00303	CcSEcCtD
Verteporfin—Pruritus—Fludarabine—lymphatic system cancer	0.00301	0.00301	CcSEcCtD
Verteporfin—Back pain—Mitoxantrone—lymphatic system cancer	0.003	0.003	CcSEcCtD
Verteporfin—Anaemia—Vincristine—lymphatic system cancer	0.00294	0.00294	CcSEcCtD
Verteporfin—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00292	0.00292	CcSEcCtD
Verteporfin—Photosensitivity—Methotrexate—lymphatic system cancer	0.00292	0.00292	CcSEcCtD
Verteporfin—Hypertension—Carmustine—lymphatic system cancer	0.00288	0.00288	CcSEcCtD
Verteporfin—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00288	0.00288	CcSEcCtD
Verteporfin—Nausea—Teniposide—lymphatic system cancer	0.00288	0.00288	CcSEcCtD
Verteporfin—Anaemia—Mitoxantrone—lymphatic system cancer	0.00287	0.00287	CcSEcCtD
Verteporfin—Vertigo—Vincristine—lymphatic system cancer	0.00286	0.00286	CcSEcCtD
Verteporfin—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00284	0.00284	CcSEcCtD
Verteporfin—Chest pain—Carmustine—lymphatic system cancer	0.00284	0.00284	CcSEcCtD
Verteporfin—Malaise—Mitoxantrone—lymphatic system cancer	0.0028	0.0028	CcSEcCtD
Verteporfin—Dyspnoea—Bleomycin—lymphatic system cancer	0.00278	0.00278	CcSEcCtD
Verteporfin—Hypertension—Vincristine—lymphatic system cancer	0.00275	0.00275	CcSEcCtD
Verteporfin—Oedema—Carmustine—lymphatic system cancer	0.00272	0.00272	CcSEcCtD
Verteporfin—Visual disturbance—Methotrexate—lymphatic system cancer	0.00271	0.00271	CcSEcCtD
Verteporfin—Cough—Mitoxantrone—lymphatic system cancer	0.00271	0.00271	CcSEcCtD
Verteporfin—Rash—Fludarabine—lymphatic system cancer	0.00268	0.00268	CcSEcCtD
Verteporfin—Dermatitis—Fludarabine—lymphatic system cancer	0.00268	0.00268	CcSEcCtD
Verteporfin—Hypertension—Mitoxantrone—lymphatic system cancer	0.00268	0.00268	CcSEcCtD
Verteporfin—Pain—Bleomycin—lymphatic system cancer	0.00267	0.00267	CcSEcCtD
Verteporfin—Headache—Fludarabine—lymphatic system cancer	0.00267	0.00267	CcSEcCtD
Verteporfin—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00264	0.00264	CcSEcCtD
Verteporfin—Chest pain—Mitoxantrone—lymphatic system cancer	0.00264	0.00264	CcSEcCtD
Verteporfin—Discomfort—Mitoxantrone—lymphatic system cancer	0.00261	0.00261	CcSEcCtD
Verteporfin—Oedema—Vincristine—lymphatic system cancer	0.0026	0.0026	CcSEcCtD
Verteporfin—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00257	0.00257	CcSEcCtD
Verteporfin—Osteoarthritis—Methotrexate—lymphatic system cancer	0.00257	0.00257	CcSEcCtD
Verteporfin—Nervous system disorder—Vincristine—lymphatic system cancer	0.00255	0.00255	CcSEcCtD
Verteporfin—Oedema—Mitoxantrone—lymphatic system cancer	0.00253	0.00253	CcSEcCtD
Verteporfin—Nausea—Fludarabine—lymphatic system cancer	0.00253	0.00253	CcSEcCtD
Verteporfin—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00251	0.00251	CcSEcCtD
Verteporfin—Shock—Mitoxantrone—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Verteporfin—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00248	0.00248	CcSEcCtD
Verteporfin—Urticaria—Bleomycin—lymphatic system cancer	0.00248	0.00248	CcSEcCtD
Verteporfin—Body temperature increased—Bleomycin—lymphatic system cancer	0.00247	0.00247	CcSEcCtD
Verteporfin—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00246	0.00246	CcSEcCtD
Verteporfin—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00245	0.00245	CcSEcCtD
Verteporfin—Dyspnoea—Carmustine—lymphatic system cancer	0.00243	0.00243	CcSEcCtD
Verteporfin—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.00237	0.00237	CcSEcCtD
Verteporfin—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00237	0.00237	CcSEcCtD
Verteporfin—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00235	0.00235	CcSEcCtD
Verteporfin—Pain—Carmustine—lymphatic system cancer	0.00233	0.00233	CcSEcCtD
Verteporfin—Constipation—Carmustine—lymphatic system cancer	0.00233	0.00233	CcSEcCtD
Verteporfin—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00231	0.00231	CcSEcCtD
Verteporfin—Hypersensitivity—Bleomycin—lymphatic system cancer	0.0023	0.0023	CcSEcCtD
Verteporfin—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00226	0.00226	CcSEcCtD
Verteporfin—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Verteporfin—Feeling abnormal—Carmustine—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Verteporfin—Asthenia—Bleomycin—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Verteporfin—Pain—Vincristine—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Verteporfin—Constipation—Vincristine—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Verteporfin—Pruritus—Bleomycin—lymphatic system cancer	0.00221	0.00221	CcSEcCtD
Verteporfin—Constipation—Mitoxantrone—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Verteporfin—Pain—Mitoxantrone—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Verteporfin—Body temperature increased—Carmustine—lymphatic system cancer	0.00215	0.00215	CcSEcCtD
Verteporfin—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00209	0.00209	CcSEcCtD
Verteporfin—Body temperature increased—Vincristine—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Verteporfin—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.00203	0.00203	CcSEcCtD
Verteporfin—Urticaria—Mitoxantrone—lymphatic system cancer	0.00201	0.00201	CcSEcCtD
Verteporfin—Hypersensitivity—Carmustine—lymphatic system cancer	0.00201	0.00201	CcSEcCtD
Verteporfin—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.002	0.002	CcSEcCtD
Verteporfin—Pneumonia—Methotrexate—lymphatic system cancer	0.00199	0.00199	CcSEcCtD
Verteporfin—Rash—Bleomycin—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Verteporfin—Dermatitis—Bleomycin—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Verteporfin—Asthenia—Carmustine—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Verteporfin—Conjunctivitis—Methotrexate—lymphatic system cancer	0.00192	0.00192	CcSEcCtD
Verteporfin—Hypersensitivity—Vincristine—lymphatic system cancer	0.00192	0.00192	CcSEcCtD
Verteporfin—Sweating—Methotrexate—lymphatic system cancer	0.0019	0.0019	CcSEcCtD
Verteporfin—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00187	0.00187	CcSEcCtD
Verteporfin—Asthenia—Vincristine—lymphatic system cancer	0.00187	0.00187	CcSEcCtD
Verteporfin—Nausea—Bleomycin—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Verteporfin—Asthenia—Mitoxantrone—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Verteporfin—Dizziness—Carmustine—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Verteporfin—Haemoglobin—Methotrexate—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Verteporfin—Haemorrhage—Methotrexate—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Verteporfin—Pharyngitis—Methotrexate—lymphatic system cancer	0.00176	0.00176	CcSEcCtD
Verteporfin—Dizziness—Vincristine—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Verteporfin—Rash—Carmustine—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Verteporfin—Dermatitis—Carmustine—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Verteporfin—Visual impairment—Methotrexate—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Verteporfin—Headache—Carmustine—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Verteporfin—Eye disorder—Methotrexate—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Verteporfin—Cardiac disorder—Methotrexate—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Verteporfin—Rash—Vincristine—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Verteporfin—Dermatitis—Vincristine—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Verteporfin—Headache—Vincristine—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Verteporfin—Nausea—Carmustine—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Verteporfin—Angiopathy—Methotrexate—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Verteporfin—Immune system disorder—Methotrexate—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Verteporfin—Rash—Mitoxantrone—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Verteporfin—Dermatitis—Mitoxantrone—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Verteporfin—Headache—Mitoxantrone—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Verteporfin—Malnutrition—Methotrexate—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Verteporfin—Nausea—Vincristine—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Verteporfin—Nausea—Mitoxantrone—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Verteporfin—Back pain—Methotrexate—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Verteporfin—Vision blurred—Methotrexate—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Verteporfin—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Verteporfin—Anaemia—Methotrexate—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Verteporfin—Malaise—Methotrexate—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Verteporfin—Vertigo—Methotrexate—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Verteporfin—Cough—Methotrexate—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Verteporfin—Arthralgia—Methotrexate—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Verteporfin—Chest pain—Methotrexate—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Verteporfin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Verteporfin—Discomfort—Methotrexate—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Verteporfin—Nervous system disorder—Methotrexate—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Verteporfin—Skin disorder—Methotrexate—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Verteporfin—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Verteporfin—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Verteporfin—Dyspnoea—Methotrexate—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Verteporfin—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Verteporfin—Pain—Methotrexate—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Verteporfin—Feeling abnormal—Methotrexate—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Verteporfin—Urticaria—Methotrexate—lymphatic system cancer	0.001	0.001	CcSEcCtD
Verteporfin—Body temperature increased—Methotrexate—lymphatic system cancer	0.000997	0.000997	CcSEcCtD
Verteporfin—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00093	0.00093	CcSEcCtD
Verteporfin—Asthenia—Methotrexate—lymphatic system cancer	0.000905	0.000905	CcSEcCtD
Verteporfin—Pruritus—Methotrexate—lymphatic system cancer	0.000893	0.000893	CcSEcCtD
Verteporfin—Dizziness—Methotrexate—lymphatic system cancer	0.000834	0.000834	CcSEcCtD
Verteporfin—Rash—Methotrexate—lymphatic system cancer	0.000796	0.000796	CcSEcCtD
Verteporfin—Dermatitis—Methotrexate—lymphatic system cancer	0.000795	0.000795	CcSEcCtD
Verteporfin—Headache—Methotrexate—lymphatic system cancer	0.00079	0.00079	CcSEcCtD
Verteporfin—Nausea—Methotrexate—lymphatic system cancer	0.000749	0.000749	CcSEcCtD
